A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies. The research, published in Clinical Cancer Research, found that measuring the interaction between two proteins, RAS and RAF, could provide valuable insights into the effectiveness of treatments for patients with KRASG12C-mutant non-small cell lung cancer, a type of lung cancer known for being particularly difficult to treat.
Go to Source
https://medicalxpress.com/rss-feed/